- SEK1.45bn
- SEK1.36bn
- SEK313.35m
Sweden's Paxman Q2 revenue rises 40% as net income turns positive
Brief: Paxman Reports Q2 Group Revenue Of SEK 105 Million
Brief: Paxman Says CMS Releases Cy2027 Proposed OPPS, MPFS Rules For Mechanical Scalp Cooling
Sweden's Paxman Q1 revenue rises 34% on Dignitana acquisition
Brief: Paxman Q1 Revenue SEK 89.6 Million
Sweden's Paxman proposes no dividend for financial year 2025
Brief: Paxman Net Sales SEK 84.4 Mln For Q4
Brief: Paxman Q4 Revenue SEK 84.4 Million
Brief: Paxman Q3 Revenue SEK 86.9 Million
Brief: Paxmann Says Limb Cryocompression Well-Tolerated In CIPN Study
Brief: Paxman Says Limb Cryocompression System Accepted Into FDA's Step
Brief: Paxman Chairman Acquired About SEK 1 Mln Worth Of Shares
Brief: Paxman Q2 Revenue SEK 74.9 Million
Brief: Paxman Updates On Takeover Bid For Dignitana
Brief: Paxman Q1 Revenue SEK 67.1 Million
Brief: Paxman Completes Public Offer To Dignitana Shareholders, Extends Acceptance Period
Brief: Paxman Makes Recommended Takeover Offer To Dignitana Shareholders
Brief: Paxman Proposes That No Dividend Shall Be Paid For 2024
Brief: Paxman Q4 Revenue SEK 66.2 Million